FindTrial
Sign In

Routine care as per site standard.

OTHER3 trials

Sponsors

iOMEDICO AG

Conditions

Chronic Lymphocytic Leukemia (CLL)Diffuse Large B-cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)Marginal Zone Lymphoma (MZL)Multiple MyelomaRenal Cell CarcinomaUrothelial Carcinoma

Unknown Phase

Myeloma Registry Platform (MYRIAM)
RecruitingNCT03308474
iOMEDICO AGMultiple Myeloma
Start: 2017-09-25End: 2028-12-01Target: 2200Updated: 2026-07-13
Registry Platform Urologic Cancer
RecruitingNCT03374267
iOMEDICO AGRenal Cell Carcinoma, Urothelial Carcinoma
Start: 2017-12-07End: 2034-03-01Target: 2230Updated: 2026-07-14
Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
RecruitingNCT06043011
iOMEDICO AGChronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) +3
Start: 2023-09-27End: 2033-12-01Target: 2950Updated: 2026-07-13

Related Papers

Head-to-head comparison of TKI and CPI first-line treatment strategies in advanced renal cell carcinoma-Real-world data from the German research platform CARAT.
2025-10-29
Comparison of TKI and CPI strategies as first-line treatment of patients with advanced renal cell carcinoma: Real-world outcome data from the German research platform CARAT.
Journal of Clinical Oncology2024-06-014 citations
Survival of non-transplant patients with multiple myeloma in routine care differs from that in clinical trials-data from the prospective German Tumour Registry Lymphatic Neoplasms.
2018-08-0129 citations